A Real-World Single-Center Cohort Study on the Tolerability of Trastuzumab Deruxtecan for HER2+ Metastatic Breast Cancer
T-DXd demonstrated acceptable tolerability with manageable AEs in real-world patients with HER2+ mBC, aligning with clinical trial outcomes and supporting its continued use in clinical practice.
Authors
- Ricardo Costa (ORCID: https://orcid.org/0000-0002-3303-3234)
- Aixa Soyano (ORCID: https://orcid.org/0000-0003-1506-5934)
- Kathrin Dvir (ORCID: https://orcid.org/0000-0002-3866-9290)
- Loretta Loftus (ORCID: https://orcid.org/0009-0004-0996-7928)
- Ameer Basta
- Melissa Armitage
- Avan Armaghani (ORCID: https://orcid.org/0000-0002-5426-3119)
- Brian J. Czerniecki (ORCID: https://orcid.org/0000-0003-4519-9570)
- Hyo S. Han (ORCID: https://orcid.org/0000-0002-0072-0257)
- Timothy Connor (ORCID: https://orcid.org/0000-0002-4615-7180)
- Junmin Whiting (ORCID: https://orcid.org/0000-0003-1515-5200)
- Weihong Sun
- Hatem Soliman (ORCID: https://orcid.org/0000-0002-1893-3808)
- Kyle Lien
Institutions
- University of South Florida (US)
- Moffitt Cancer Center (US)
Publication Details
- Journal
- Oncology
- Published
- 2025-08-04
- DOI
- https://doi.org/10.1159/000547685
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00